Evidence map›Paper›PMID 35711466›Full record

ReviewFrontiers in immunology2022

COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes.

Banafsheh Bigdelou, Mohammad Reza Sepand, Sahar Najafikhoshnoo, Jorge Alfonso Tavares Negrete, Mohammed Sharaf, Jim Q Ho, Ian Sullivan, Prashant Chauhan, Manina Etter, Tala Shekarian and 4 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Banafsheh BigdelouDepartment of Bioengineering, University of Massachusetts Dartmouth, Dartmouth, MA, United States.
Mohammad Reza SepandDepartment of Bioengineering, University of Massachusetts Dartmouth, Dartmouth, MA, United States.
Sahar NajafikhoshnooDepartment of Electrical Engineering, University of California, Irvine, CA, United States.
Jorge Alfonso Tavares NegreteDepartment of Electrical Engineering, University of California, Irvine, CA, United States.
Mohammed SharafDepartment of Chemical and Biomolecular Engineering, New York University, New York, NY, United States.
Jim Q HoDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, United States.
Ian SullivanDepartment of Bioengineering, University of Massachusetts Dartmouth, Dartmouth, MA, United States.
Prashant ChauhanInstitute of Parasitology, Biology Centre Czech Academy of Science, Ceske Budejovice, Czech Republic.
Manina EtterDepartment of Neurosurgery, University Hospital Basel, Basel, Switzerland.
Tala ShekarianDepartment of Neurosurgery, University Hospital Basel, Basel, Switzerland.
Olin LiangDivision of Hematology/Oncology, Department of Medicine, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, RI, United States.
Gregor HutterDepartment of Neurosurgery, University Hospital Basel, Basel, Switzerland.
Rahim EsfandiarpourDepartment of Electrical Engineering, University of California, Irvine, CA, United States.
Steven ZanganehDepartment of Bioengineering, University of Massachusetts Dartmouth, Dartmouth, MA, United States.
University of Massachusetts Dartmouth · USUniversity Hospital of Basel · CHUniversity of California, Irvine · USAlbert Einstein College of Medicine · USCzech Academy of Sciences, Biology Centre · CZNew York University · USRhode Island Hospital · US

Funding

Stem Cells and AgingP20GM119943 · NIGMS · RHODE ISLAND HOSPITAL · PI WEBB, ASHLEY E · 2017 to 2021
$10.6M
NIGMS NIH HHS P20 GM119943
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated symptoms, named coronavirus disease 2019 (COVID-19), have rapidly spread worldwide, resulting in the declaration of a pandemic. When several countries began enacting quarantine and lockdown policies, the pandemic as it is now known truly began. While most patients have minimal symptoms, approximately 20% of verified subjects are suffering from serious medical consequences. Co-existing diseases, such as cardiovascular disease, cancer, diabetes, and others, have been shown to make patients more vulnerable to severe outcomes from COVID-19 by modulating host-viral interactions and immune responses, causing severe infection and mortality. In this review, we outline the putative signaling pathways at the interface of COVID-19 and several diseases, emphasizing the clinical and molecular implications of concurring diseases in COVID-19 clinical outcomes. As evidence is limited on co-existing diseases and COVID-19, most findings are preliminary, and further research is required for optimal management of patients with comorbidities.

Indexed as

COVID-19Communicable Disease ControlHumansPandemicsQuarantineSARS-CoV-2cancercardiovascular diseasecoronavirus disease 2019COVID-19diabetesimmune responsestreatment implications

Identifiers

PMID35711466
PMCPMC9196863
OpenAlexW4281642119

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.